Differences in the ARID-1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix

APMIS

Volumn 123, Issue 10, 2015, Pages 847-850

  Solakoglu Kahraman, Dudu ^a   Diniz, Gulden ^a   Sayhan, Sevil ^a   Ayaz, Duygu ^a   Uncel, Melek ^a   Karadeniz, Tugba ^a   Akman, Tulay ^a   Ozdemir, Aykut ^a  

^a TEPECIK EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adenosquamous carcinoma; ARID 1A; Squamous cell carcinoma; Uterine cervix

Indexed keywords

AT RICH INTERACTIVE DOMAIN 1A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EVALUATION STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE UTERINE CERVIX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; TISSUE LEVEL; TUMOR DIFFERENTIATION; UTERINE CERVIX ADENOSQUAMOUS CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; BIOSYNTHESIS; CELL DIFFERENTIATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX; UTERINE CERVIX TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DOWN-REGULATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84942364843     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12435     Document Type: Article

References (19)

1. Lida K, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 2011;105:420-7.
2. Kurman RJ, Ellenson LH, Ronnett BM. Bleustein's Pathology of the Female Genital Tract. Sixth Ed. New York: Springer, 2011: 286-7.
3. Contag SA, Gostout BS, Clayton AC, Dixon MH, McGovern RM, Calhoun ES. Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol 2004;95:610-7.
4. Yan M, Zhang YN, He JH, Huang H. Prognosis analysis of 83 cases of cervical adenosquamous carcinoma. Chinese J Cancer 2008;27:242-7.
5. Patsialou A, Wilsker D, Moran E. DNA-binding properties of ARID family proteins. Nucleic Acids Res 2005;33:66-80.
6. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosom Cancer 2007;46:745-50.
7. Wang X, Nagl NG, Flowers S, Zweitzig D, Dallas PB, Moran E. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer 2004;112:636.
8. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 2014;5:5295-303.
9. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011;35:625-32.
10. Abe H, Maeda D, Hino R, Otake Y, Isogai M, Ushiku AS, et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 2012;461:367-77.
11. Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol 2013;26:428-34.
12. Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Ellis C, Driscoll T, et al. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Hum Pathol 2014;45:2233-9.
13. Bosse T, ter Haar NT, Seeber LM, Diest PJ, Hes FJ, Vasen HF, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 2013;26:1525-35.
14. Zhao J, Liu C, Zhao Z. ARID1A: A potential prognostic factor for breast cancer. Tumor Biol 2014;35:4813-9.
15. Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012;22:1310-5.
16. Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH. Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol 2013;44:1365-74.
17. Yokoyama Y, Matsushita Y, Shigeto T, Futagami M, Mizunuma H. Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol 2014;25:58-63.
18. Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012;7:e40364.
19. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Ishikawa M, et al. Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix. Int J Gynecol Cancer 2012;22:208-12.